Evidence map›Paper›PMID 24379638›Full record

SynthesisWorld journal of gastroenterology2013

Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: a systematic review.

Qing Liu, Chen-Chen Feng, Er-Man Wang, Xiu-Juan Yan, Sheng-Liang Chen

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2017
    Review
  9. Electroacupuncture for Functional Constipation: A Multicenter, Randomized, Control Trial.Evidence-based complementary and alternative medicine : eCAM · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Qing LiuQing Liu, Chen-Chen Feng, Er-Man Wang, Xiu-Juan Yan, Sheng-Liang Chen, Department of Gastroenterology, Ren Ji Hospital, School of Medicine, Shanghai Institute of Digestive Disease, Shanghai Jiao Tong University, Shanghai 200001, China.
Chen-Chen FengQing Liu, Chen-Chen Feng, Er-Man Wang, Xiu-Juan Yan, Sheng-Liang Chen, Department of Gastroenterology, Ren Ji Hospital, School of Medicine, Shanghai Institute of Digestive Disease, Shanghai Jiao Tong University, Shanghai 200001, China.
Er-Man WangQing Liu, Chen-Chen Feng, Er-Man Wang, Xiu-Juan Yan, Sheng-Liang Chen, Department of Gastroenterology, Ren Ji Hospital, School of Medicine, Shanghai Institute of Digestive Disease, Shanghai Jiao Tong University, Shanghai 200001, China.
Xiu-Juan YanQing Liu, Chen-Chen Feng, Er-Man Wang, Xiu-Juan Yan, Sheng-Liang Chen, Department of Gastroenterology, Ren Ji Hospital, School of Medicine, Shanghai Institute of Digestive Disease, Shanghai Jiao Tong University, Shanghai 200001, China.
Sheng-Liang ChenQing Liu, Chen-Chen Feng, Er-Man Wang, Xiu-Juan Yan, Sheng-Liang Chen, Department of Gastroenterology, Ren Ji Hospital, School of Medicine, Shanghai Institute of Digestive Disease, Shanghai Jiao Tong University, Shanghai 200001, China.
Shanghai Liangyou (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the potential benefits of mosapride plus proton pump inhibitors (PPIs) in the treatment of gastroesophageal reflux disease.

methodsA literature search was performed through MEDLINE, EMBASE, and the ISI Web of Knowledge. The clinical trials that compared the benefit of mosapride plus PPI treatment with that of PPI monotherapy were analyzed. The rate of responders was evaluated by the pooled relative risk (PRR) and improvement in symptom scores was assessed by single effect size of a standardized mean, while Hedges'g was used as the effect size. Pooled effect sizes with 95%CIs were calculated using a fixed-effects model. Between-study heterogeneity was assessed using Q test and I (2) analyses. In addition, studies that assessed the additional efficacy of mosapride in PPI-resistant patients were also reviewed.

resultsThis systematic review included information on a total of 587 patients based on 7 trials. Four trials compared the efficacy of combination therapy of mosapride plus a PPI with that of PPI monotherapy. The statistical analysis for the effect of additional mosapride showed equivocal results (PRR = 1.132; 95%CI: 0.934-1.372; P = 0.205; Hedges'g = 0.24; 95%CI: 0.03-0.46; P = 0.023). No heterogeneity and publication bias were found among the studies. Three open-labeled trials assessed the additional efficacy of mosapride in PPI-resistant patients. However, since these trials did not set the control group, the results may be considerably biased.

conclusionMosapride combined therapy is not more effective than PPI alone as first-line therapy. Whether it is effective in PPI-resistant patients needs to be determined.

Indexed as

BenzamidesDrug Therapy, CombinationGastroesophageal RefluxHumansMorpholinesProton Pump InhibitorsSerotonin Receptor AgonistsTreatment OutcomeBenzamidesMorpholinesmosaprideProton Pump InhibitorsSerotonin Receptor AgonistsCombined therapyGastroesophageal reflux diseaseMosaprideProton pump inhibitorSystematic review

Identifiers

PMID24379638
PMCPMC3870566
OpenAlexW2084253090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.